SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market
DNA Link will bring the power of the largest proteomics platform available to their biomarker discovery and drug development work
News provided bySomaLogic
Sep 19, 2023, 4:30 PM ET
BOULDER, Colo. and SEOUL, Korea, Sept. 19, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced its partnership with DNA Link, an innovator in personalized and precision medicine, to offer the 7,000-plex SomaScan® platform to their customers. DNA Link will be the first SomaLogic authorized site in Korea.
“Over the past 20 years, DNA Link has cultivated a reputation for generating and interpreting high-quality genomic data,” said Chief Executive Officer of DNA Link, Lee Jong-eun. “By bringing expanded proteomics capabilities through SomaLogic to our offerings, we can add to our abilities in biomarker discovery and drug development in Korea and across Asia, ultimately contributing to improving human health and quality of life.”
SomaLogic’s 7,000-plex SomaScan assay will significantly expand DNA Link’s proteomics capabilities in its laboratory in Seoul, Korea. DNA Link has been conducting genomics research from its labs for more than two decades with a focus on genetic epidemiology, drug development and personalized medicine. Their multiomics offerings are available in Korea and across Asia.
“Korea is a major contributor to the fast-growing proteomics market in the Asia Pacific region due to an increase in research funding, especially around personalized therapeutics and the growing awareness of proteomics technology and what it can offer,” said SomaLogic Chief Executive Officer Adam Taich. “We’re looking forward to supporting DNA Link in expanding the use of proteomics for research in this region.”
For more than twenty years, SomaLogic has grown from its roots in the research lab to become a global leader in proteomics with technology that delivers the quality and quantity of biological insights life science researchers need - from lab to last mile.
SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at somalogic.com and follow @somalogic on LinkedIn.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
NOTE: This content is not written by or endorsed by "KLAS", its advertisers, or Nexstar Media Inc.